Pulmonary complications are fatal adverse events after allogeneic hematopoietic cell transplantation (allo-HCT). On the other hand, smoking is a well-known risk factor for various pulmonary diseases and also increases the incidence of pulmonary complications and overall mortality in allo-HCT recipients. In this study, we retrospectively assessed the impact of smoking intensity on survival outcomes. This study included consecutive allo-HCT recipients at our center between June 2007 and May 2019 whose smoking profiles were available (n = 408); they were divided into high (pack-years >10, n = 171) and low (pack-years ≤10, n = 231) pack-years groups. In univariate analyses, nonrelapse mortality (NRM) and overall survival (OS) were significantly inferior in the high pack-years group (1-year NRM 26.6% versus 13.9%, P < .001; 1-year OS 58.4% versus 70.1%, P = .0067). However, this association was not observed in multivariate analyses. In subgroup analyses according to sex, the survival outcomes in the high pack-years group were significantly inferior in males (NRM hazard ratio [HR], 2.24 [95% confidence interval (CI), 1.23 to 4.07], P = .0082; OS HR, 1.54 [95% CI, 1.04 to 2.28], P = .031), but not in females (NRM HR, 0.587 [95% CI, 0.241 to 1.43], P = .24; OS HR, 0.689 [95% CI, 0.400 to 1.19], P = .18). In summary, high pack-years were associated with inferior survival of allo-HCT recipients, especially in males.

中文翻译：

---

吸烟对异基因移植结果的影响：单中心分析。

肺部并发症是异基因造血细胞移植 (allo-HCT) 后的致命不良事件。另一方面，吸烟是众所周知的各种肺部疾病的危险因素，并且还会增加 allo-HCT 接受者肺部并发症的发生率和总体死亡率。在这项研究中，我们回顾性地评估了吸烟强度对生存结果的影响。本研究包括 2007 年 6 月至 2019 年 5 月期间在我们中心连续接受 allo-HCT 的患者，他们的吸烟资料可用（n = 408）；他们被分为高（包年> 10，n = 171）和低（包年≤10，n = 231）包年组。在单变量分析中，高包年组的非复发死亡率 (NRM) 和总生存期 (OS) 明显较差（1 年 NRM 26.6% 对 13.9%，P < .001；1 年 OS 58。4% 对 70.1%，P = .0067）。然而，在多变量分析中没有观察到这种关联。在根据性别进行的亚组分析中，男性高包年组的生存结果明显较差（NRM 风险比 [HR]，2.24 [95% 置信区间 (CI)，1.23 至 4.07]，P = .0082； OS HR，1.54 [95% CI，1.04 到 2.28]，P = 0.031），但在女性中没有（NRM HR，0.587 [95% CI，0.241 到 1.43]，P = .24；OS HR，0.689 [95 % CI，0.400 至 1.19]，P = .18)。总之，高包年与allo-HCT 受者的低生存率相关，尤其是在男性中。1.23 至 4.07]，P = .0082；OS HR，1.54 [95% CI，1.04 到 2.28]，P = 0.031），但在女性中没有（NRM HR，0.587 [95% CI，0.241 到 1.43]，P = .24；OS HR，0.689 [95 % CI，0.400 至 1.19]，P = .18)。总之，高包年与allo-HCT 受者的低生存率相关，尤其是在男性中。1.23 至 4.07]，P = .0082；OS HR，1.54 [95% CI，1.04 到 2.28]，P = 0.031），但在女性中没有（NRM HR，0.587 [95% CI，0.241 到 1.43]，P = .24；OS HR，0.689 [95 % CI，0.400 至 1.19]，P = .18)。总之，高包年与allo-HCT 受者的低生存率相关，尤其是在男性中。